Downloads: 0
Research Paper | Ophthalmology | Volume 15 Issue 5, May 2026 | Pages: 921 - 926 | Cambodia
Visual and Anatomical Outcomes of Intravitreal Bevacizumab for Diabetic Macular Edema at Preah Ang Duong Hospital
Abstract: Purpose: This study was conducted to evaluate the visual outcomes of intravitreal Bevacizumab in patients with diabetic macular edema (DME) treated at Preah Ang Duong Hospital. The primary outcome measure was improvement in best-corrected visual acuity (BCVA), while secondary outcomes included reduction in central macular thickness (CMT), intraocular pressure (IOP) changes, treatment safety, and sustainability of visual improvement during follow-up. Methods: This was a prospective hospital-based study involving 97 patients with diabetic macular edema who received monthly intravitreal Bevacizumab injections at Preah Ang Duong Hospital, Phnom Penh, Cambodia. Baseline and follow-up assessments included socio-demographic characteristics, systemic comorbidities, BCVA, CMT measured by optical coherence tomography, IOP, and adverse events. Data were entered using EpiData and imported into SPSS version 25 for statistical analysis. Descriptive statistics were presented as mean, standard deviation, frequency, and percentage. Baseline and follow-up outcomes were compared using paired t-test and repeated-measures ANOVA, with a p-value < 0.05 considered statistically significant. Results: The mean age of patients was 58.4 ± 9.3 years, ranging from 34 to 79 years, and 52 patients (53.6%) were male. Most participants had type 2 diabetes mellitus (90.7%), and the most common systemic comorbidity was hypertension (49.5%). Mean baseline BCVA was 0.68 ± 0.32 logMAR and improved to 0.42 ± 0.28 logMAR after treatment, with a mean improvement of 0.26 logMAR (p < 0.001). Mean baseline CMT decreased from 455 ± 98 ?m to 312 ± 74 ?m, with a mean reduction of 143 ?m (p < 0.001). Mean IOP changed from 15.1 ± 3.1 mmHg to 15.8 ± 3.4 mmHg, with no statistically significant increase (p = 0.18). Visual improvement was maintained throughout the follow-up period. Adverse events were observed in 8.2% of patients and were limited to minor complications, including subconjunctival hemorrhage, mild ocular pain, and transient IOP rise. No serious complications were recorded. Conclusion: Intravitreal Bevacizumab significantly improved visual acuity and reduced central macular thickness in patients with diabetic macular edema over the study period, with no serious safety concerns observed. These findings support its practical use in resource-limited clinical settings.
Keywords: Diabetic Macular Edema, Bevacizumab, Intravitreal Anti-VEGF, Optical Coherence Tomography, Visual Acuity, Cambodia
How to Cite?: Vong Virak Ou, Leng Un, Lykheang Lou, Ratneary Hav, Saly Saint, Piseth Kong, "Visual and Anatomical Outcomes of Intravitreal Bevacizumab for Diabetic Macular Edema at Preah Ang Duong Hospital", Volume 15 Issue 5, May 2026, International Journal of Science and Research (IJSR), Pages: 921-926, https://www.ijsr.net/getabstract.php?paperid=SR26512161251, DOI: https://dx.dx.doi.org/10.21275/SR26512161251